{
    "clinical_study": {
        "@rank": "23590", 
        "brief_summary": {
            "textblock": "To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's\n      sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic\n      effects of Ro 24-7429 in this patient population. To explore relationships between exposure\n      to Ro 24-7429 and its metabolites with its antitumor and antiviral activities and drug\n      toxicity."
        }, 
        "brief_title": "A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV seropositivity.\n\n          -  Biopsy-proven mucocutaneous Kaposi's sarcoma with fewer than 50 skin lesions and\n             measurable disease.\n\n          -  No active opportunistic infection. NOTE:\n\n          -  Patients with CD4 count >= 200 cells/mm3 must have no prior opportunistic infection,\n             as well as no active opportunistic infection.\n\n          -  Life expectancy of at least 24 weeks.\n\n          -  Stable weight (+/- 2 kg) by 28 days prior to study entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Other active malignancies (except basal cell carcinoma of the skin and in situ\n             cervical cancer).\n\n          -  Known or suspected hypersensitivity to benzodiazepines.\n\n          -  Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal,\n             endocrine, hematologic, psychiatric, neurologic, dermatologic, or allergic disease as\n             determined by the investigator.\n\n          -  Ongoing diarrhea (> two liquid stools per day).\n\n          -  Grade 2 or worse signs and symptoms of AIDS Dementia Complex.\n\n          -  Alteration of mental status that may interfere with study compliance.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  AZT, ddI, or ddC.\n\n          -  Experimental antiretrovirals.\n\n          -  Biologic response modifiers or immunomodulating agents (e.g., interferon).\n\n          -  Colony stimulating factors (erythropoietin, GM-CSF, G-CSF).\n\n          -  Ganciclovir.\n\n          -  Foscarnet.\n\n          -  H-2 antagonists (cimetidine, ranitidine, famotidine, nizatidine).\n\n          -  Omeprazole.\n\n          -  Benzodiazepines.\n\n          -  Any other investigational compound.\n\n          -  Ongoing systemic treatment with corticosteroids (other than replacement therapy for\n             adrenal insufficiency or short-term therapy of no more than 28 days for bronchial\n             asthma).\n\n          -  Cytotoxic chemotherapy (systemic and local).\n\n          -  Drugs known to cause systemic toxicity, if avoidable (e.g., myelosuppressive,\n             hepatotoxic, nephrotoxic, or neurotoxic drugs).\n\n          -  Paromomycin sulfate.\n\n          -  Chronic suppressive therapy for CMV and/or MAI.\n\n        Patients with the following prior condition are excluded:\n\n        History of serious adverse reactions to benzodiazepines.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Interferons or immune modulators within 4 weeks prior to study entry.\n\n          -  Prior systemic cytotoxic chemotherapy (patients with CD4 counts >= 200 cells/mm3\n             only).\n\n          -  Benzodiazepines within 14 days prior to study entry.\n\n          -  Intralesional chemotherapy for Kaposi's sarcoma within 2 weeks prior to study entry.\n\n          -  Therapy with antiretroviral drugs (including AZT, ddI, ddC, d4T) or investigational\n             drugs within 14 days prior to study entry.\n\n        Localized radiotherapy. Radiotherapy (other than localized). Active drug or alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002314", 
            "org_study_id": "128A"
        }, 
        "intervention": {
            "intervention_name": "Ro 24-7429", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antineoplastic Agents"
        }, 
        "keyword": [
            "Sarcoma, Kaposi", 
            "Acquired Immunodeficiency Syndrome", 
            "Antineoplastic Agents", 
            "Gene Products, tat"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "900951793"
                    }, 
                    "name": "CARE Ctr / UCLA Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "New England Deaconess Hosp"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV-Related Kaposi's Sarcoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002314"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1993"
    }, 
    "geocoordinates": {
        "CARE Ctr / UCLA Med Ctr": "34.052 -118.244", 
        "New England Deaconess Hosp": "42.358 -71.06"
    }
}